TVRD logo

TVARDI THERAPEUTICS INC

TVRDNASDAQ
🏆 #4940 by market capEarnings Nov 11US Equity
$1.29▼ $0.03 (−2.64%)
After hours · at close
🔔
Track TVRD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.6%
7d▼ 18.9%
14d▼ 26.7%
30d▼ 28.3%
ytd▼ 70.1%
1y▼ 96.5%
🏦Market Cap
$12M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$1.28 – $1.30
52-Week Range
$0.93 – $43.65
Volume
$2.44B
Avg Volume
$2.29B
Shares Outstanding
9.4M
Next Earnings
Oct 30, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$468,014
P/E Ratio
-0.5
P/S Ratio
0.0x
EPS (TTM)
$-2.79
Dividend Yield
0.00%
Dilution (1yr)
+515.6%

Why Investors Own TVRD

  • ✓High-growth profile — revenue up +58.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 58% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TVRD logo

TVARDI THERAPEUTICS INC

TVRD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
88.6%▲ +27.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$27M▼ −52.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$23M▼ −62.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.4M▲ +515.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$21M▲ +$27M YoY
StockOtter · stockotter.space

About TVARDI THERAPEUTICS INC

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Ratings

ⓘ
Consensus
Buy
14 analysts
Strong Buy4
Buy7
Hold2
Sell1
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

TVARDI THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift TVRD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

TVARDI THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.